Cephalexin for Oral Suspension, USP 125 mg per 5 mL, For Reconstitution, For Oral Use Only, Rx Only, a) 100 mL bottle when mixed, NDC 0093-4175-73, b) 200 mL bottle when mixed, NDC 0093-4175-74, Teva Pharmaceuticals USA, Inc., North Wales, PA 19454.
Published September 16, 2020 · Recall initiated: August 24, 2020
Summary
FDA records drug Class II recall D-0012-2021, published September 16, 2020 and initiated August 24, 2020. Recalling firm: Teva Pharmaceuticals USA; Status: Terminated; Reported quantity: 103,940 bottles; Lot: Lot #s: a) 30309820A, Exp. 08/2020; 30310000B, 30310001B, Exp. 10/2020; 30310096A Exp. 01/2021; 30310228A, Exp. 03/2021; 30310313A, Exp. 06/2021; b) 30309861A, Exp. 08/2020; 30310335A, Exp. 06/2021. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.
Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.
What's the hazard
CGMP deviations; there is a possibility that some bottles in these lots may have the active ingredient above and/or below specification limits.
What to do
Voluntary: Firm initiated · Letter
Get an email if CEPHALEXIN has another recall
Free. We only write when there's a new recall that matches. Unsubscribe in one click.
Recall details
- Brand
- CEPHALEXIN
- Manufacturer
- Teva Pharmaceuticals USA
- Distributor
- Nationwide in the U.S. and Puerto Rico.
- UPC
- 0300934175738
- Lot
- Lot #s: a) 30309820A, Exp. 08/2020; 30310000B, 30310001B, Exp. 10/2020; 30310096A Exp. 01/2021; 30310228A, Exp. 03/2021; 30310313A, Exp. 06/2021; b) 30309861A, Exp. 08/2020; 30310335A, Exp. 06/2021.
- Risk classification
- Class II
- Area (FDA)
- drug
- Country
- United States
Related recalls
- FDACephalexin for Oral Suspension, USP, 125 mg per 5 mL, 100 mL (when mixed), Rx Only, Manufactured by: AlkemJune 18, 2025
- FDACephalexin for Oral Suspension, USP, 125 mg per 5 mL, 200 mL (when mixed), Rx Only, Manufactured by: AlkemJune 18, 2025
- FDACephalexin for Oral Suspension, USP, 250mg per 5mL, Rx only, 100mL (when mixed), Each contains cephalexinJune 12, 2024
- FDACephalexin for Oral Suspension, USP, 125mg per 5mL, Rx only, 200mL (when mixed), Each contains: cephalexinJune 12, 2024
- FDACephalexin for Oral Suspension, USP 250 mg per 5 mL, For Reconstitution, For Oral Use Only, Rx Only, a) 100 mLSeptember 16, 2020
- FDAParvovirus B19 IgG EIA kit Part No. V519IGUSSeptember 9, 2020
Questions about this recall
Was Cephalexin for Oral Suspension, USP 125 mg per 5 mL, For Reconstitution, For Oral Use Only, Rx Only, a) 100 mL bottle when mixed, NDC 0093-4175-73, b) 200 mL bottle when mixed, NDC 0093-4175-74, Teva Pharmaceuticals USA, Inc., North Wales, PA 19454. recalled?
Yes. FDA published recall D-0012-2021 on September 16, 2020. Reported hazard: CGMP deviations; there is a possibility that some bottles in these lots may have the active ingredient above and/or below specification limits.
What should I do if I have this product?
Voluntary: Firm initiated · Letter
How do I know if my unit is part of the recall?
Compare your product details with the notice. Brand: CEPHALEXIN. UPC: 0300934175738.